The sales performance of Chinese biopharma was stable in May 2025, BofA Securities issued a research report saying. BEIGENE (06160.HK) -4.400 (-2.426%) Short selling $220.30M; Ratio 21.866% (ONC.US) reported a YoY sales increase of 17.5% for its self-developed drugs and 19.3% for in-licensed products. Its two core products, naming tislelizumab and tarlatamab, received new indication approvals and launch application acceptance. Accordingly, the broker raised its 2026/ 2027 revenue forecasts by 0.2-0.3%, and elevated its target prices for BEIGENE's US stock/ H-shares from US$300/ $181.15 to US$340/ $205.31, with rating kept at Buy.Related NewsHSBC Research Lists H-Shrs Most Favored by Domestic Active Mutual Funds/ Southbound Capital in 2Q (Table)ZAI LAB (09688.HK) -0.450 (-1.533%) Short selling $44.42M; Ratio 9.570% (ZLAB.US) saw a 17% YoY increase in sample drug sales in May, with core product Ripretinib growing by 44.1% and Omadacycline increasing by 20%, BofA Securities added. The company recently also announced that the Phase 3 trial for bemarituzumab reached its primary endpoint of overall survival. Based on the company's drug sales growth and pipeline progress, the broker lifted its 2025-2027 revenue forecasts by 0.3-0.6%, and raised its target prices for ZAI LAB's H-shares/ US stock from $29.61/ US$38.2 to $32.09/ US$41.4, with rating kept at Neutral.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-08-01 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)